Most guidelines recommend brain imaging in HER2-positive metastatic breast cancer only when neurological symptoms appear. Griguolo et al.: Annual proactive brain CT screening → fewer symptomatic brain metastases and better performance status. But an important question remains: In the era of new anti-HER2 therapies (T-DXd, tucatinib, etc.), will the natural history of brain metastases change — and will screening strategies still carry the same clinical value? Results of the proactive annual brain CT screening study by Griguolo et al.: * earlier detection of asymptomatic brain metastases * fewer symptomatic presentations (0% vs 9.5%) * better performance status at the time of brain metastasis diagnosis @oncodaily @OncBrothers @PTarantinoMD @tompowles1 @Dr_Oncologista @myESMO @ASCOPost aacrjournals.org/clincancerres/…
